Bulevirtide Acetate

CHEMBL5315080 Phase 4 Aprovado Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

An entry inhibitor used to treat chronic hepatitis delta virus infection in adults with compensated liver disease. It works by blocking the sodium taurocholate cotransporting polypeptide receptor that the hepatitis D virus uses to enter liver cells. It is the first approved therapy specifically targeting hepatitis delta.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An entry inhibitor used to treat chronic hepatitis delta virus infection in adults with compensated liver disease. It works by blocking the sodium taurocholate cotransporting polypeptide receptor that the hepatitis D virus uses to enter liver cells. It is the first approved therapy specifically targeting hepatitis delta.

Yes, Bulevirtide Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315080. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Procura informações acessíveis para o paciente?

Bulevirtide Acetate no PillFYI

Dados Rápidos

Links Externos

ChEMBL CHEMBL5315080

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.